Arcus Biosciences Inc expected to post a loss of $1.02 a share - Earnings Preview

Arcus Biosciences

19/02/2024 21:46

* Arcus Biosciences Inc  RCUS.N   RCUS.K  is expected
to show a
fall in quarterly revenue when it reports  results on February
21 for the period ending December 31 2023
    * The Hayward California-based  company is expected to
report a
16.6% decrease in revenue to $28.368 million from $34 million a
year ago, according to the mean estimate from 10 analysts, based
on LSEG data.
    * ​LSEG's mean analyst estimate for Arcus Biosciences Inc is
for a
loss of $1.02 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Arcus
Biosciences
Inc is $35.00​, above​ its last closing price of $16.80. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -1.12       -1.13      -0.94     Beat    16.7
 Jun. 30 2023  -1.09       -1.10      -1.04     Beat    5.3
 Mar. 31 2023  -1.17       -1.16      -1.09     Beat    6.3​
 Dec. 31 2022  -1.02       -1.07      -0.93     Beat    
 ​​Sep.        -1.03       -1.04      -0.90     Beat    13.3
 30 2022                                                
 Jun. 30 2022  -0.94       -0.94      -0.93     Beat    1.2​
 Mar. 31 2022  -0.83                  -0.96             -11.5
 Dec. 31 2021  0.07        -0.74      3.71      Beat    598.8
 This summary was machine generated February 19 at 21:46 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)